The aim of this study was to describe the prevalence, patterns of blood use and outcomes of major haemorrhage in trauma.
Introduction
Trauma haemorrhage makes a considerable contribution to the global burden of disease, yet its natural history and outcomes at a population level remain unclear and underappreciated. Bleeding following injury is estimated to be responsible for more than 2 million deaths annually, and even in specialist centres massive haemorrhage may carry a hospital mortality rate of over 50 per cent 1 -4 . The overall incidence and outcomes of trauma haemorrhage are not well described across a health system. New management strategies have been introduced, which include the rapid and consistent administration of transfusion therapy to correct coagulopathy 5, 6 . Although seemingly effective in the context of academic trauma centres 7 , it is not clear how effectively these strategies have been implemented or how successful they are across the board 8 . There may be important opportunities for improvement if real-world management patterns can be described and mapped against current best practice.
In recent years there has been increasing interest in trauma haemorrhage, as civilian and military studies have focused on these potentially preventable deaths. Discovery of the endogenous acute traumatic coagulopathy has led to a new management paradigm of damage control resuscitation 9 . This strategy focuses on the early delivery of red blood cells and high doses of plasma fractions 10 -16 to maintain haemostatic potential by treating the early coagulopathy and preventing further dilution of factors. In some reports these strategies have appeared to halve the risk of death in the most severely bleeding patients. However, the rapid and consistent delivery of blood, plasma, platelets and other products can be extremely challenging in the emergency environment, and delays and gaps in product availability can occur. In particular, the early availability of blood components and the ability to deliver them consistently in high doses alongside red blood cells appears to be important in maintaining haemostatic competence. Although there has been broad acceptance of the concepts in damage control resuscitation, challenges with implementation may reduce its effectiveness.
The overall objective of this study was to describe the current status of severe trauma haemorrhage at a national level in the UK, by conducting a prospective observational study at a sample of 22 trauma receiving hospitals across England and Wales. The first aim was to determine the overall incidence of trauma haemorrhage across the population. Additional aims were to determine the population outcome of trauma haemorrhage in terms of immediate, hospital and long-term mortality, and to describe the delivery of red cells and other blood components during haemorrhage resuscitation to understand existing practice and identify opportunities for improvement.
Methods
A prospective multicentre cross-sectional observational study was conducted in collaboration with the Trauma Audit and Research Network (TARN), an independent monitor of trauma care in England and Wales. Hospitals that participate in TARN collect data on all TARN-eligible trauma admissions, including characteristics of the injury, details of interventions, such as surgical or radiological investigations, and patient outcomes, including deaths in hospital and survival status at 30 days after discharge.
Participating centres
The selection of participating trauma departments was based on geographical distribution across England and size of hospital or emergency department, in order to ensure an approximately equal regional distribution between large, multispecialty trauma centres and medium-sized hospitals with trauma units. The selection of participating hospitals was also based on local support and interest from senior medical staff, and centres with a record of consistent participation in TARN during audit quality control.
Inclusion and exclusion criteria
Eligible patients were adult injured patients aged 16 years and over admitted to the 22 trauma receiving hospitals who fulfilled the TARN inclusion criteria: injuries that result in a hospital stay of 72 h or more, transfer for specialist or intensive care, or patient death. In addition, eligible patients had to have received at least 4 units of packed red blood cells (PRBCs) in the first 24 h of admission, with activation of the massive haemorrhage protocol (MHP) 17, 18 . The rationale for requiring MHP activation was to identify the more severely injured bleeding patients. An organizational questionnaire was used to obtain details of the MHP and its activation from all 22 centres. Patients transferred from another hospital were excluded. Patients who received at least 4 units of PRBCs in the first 24 h were classified as having major haemorrhage, and those receiving 10 units or more as having massive haemorrhage.
Patient-level outcome measures and data collection
Outcome measures were: 24-h, 30-day and 1-year mortality, critical care during hospital stay, ventilator-free days, total length of stay, and transfusion requirements including use of PRBCs, fresh frozen plasma (FPP), platelets and cryoprecipitate. Severe injury was defined by an Injury Severity Score (ISS; 2008 version) exceeding 15. Following local approval, the TARN data coordinator allocated a unique anonymized identifying number aside from the patient's hospital number. Additional data fields were created on the existing encrypted and password-protected electronic web-based tool at TARN to collect information on use of blood components and timings of transfusions. Educational sessions and materials were provided to TARN coordinators at the participating hospitals. Local source data included patient case notes, transfusion prescription charts and blood bank records. In addition, anonymized copies of all the prescription charts and theatre charts for the first 24 h after admission were requested for central review, both to provide data and as a quality control check, undertaken in duplicate by two members of the research team.
Regulatory approvals
The National Research Ethics Committee South Central Oxford B gave full ethical approval. TARN already had Patient Information Advisory Group approval for data collection to conduct research on anonymized data without consent. A separate application to the National Information Governance Board Ethics and Confidentiality Committee and National Health Service (NHS) Medical Register Information Centre allowed the processing of patient identifiable information without consent and the collection of 1-year survival/mortality data for participants.
Data analysis
Continuous data were summarized using mean(s.d.) values, or median (i.q.r.) if not distributed normally. For hourly intervals during the first 24 h after admission, the number of units of PRBCs, FFP, cryoprecipitate and platelets administered was counted, and the mean across all patients calculated. The mean values were used on an hourly basis as many patients did not receive FFP or PRBCs. The median (i.q.r.) of the ratio of the cumulative number of units of FFP to the cumulative number of units of PRBCs was also calculated for each hour. Medians were used as the distributions of the ratios across all patients each hour were skewed. Logistic regression was used to assess the association between PRBC requirement and mortality.
Dates of death and limited information on causes of death were collected for patients who died within a year of injury. TARN also provided data for all patients who satisfied the TARN inclusion criteria during the study interval, and received at least 1 unit of PRBCs or blood components. All analysis was performed using the statistical software SAS ® version 9.1.3 (SAS Institute, Cary, North Carolina, USA). On the assumption that the TARN data were representative nationally, the percentage of major haemorrhages associated with the traumas reported to TARN by the study centres was assumed to apply to the number of patients requiring transfusion support, as defined by meeting the TARN inclusion criteria, reported to HES (1⋅4 per cent) over the interval. This allowed estimates of the number of major haemorrhage cases per year in England and Wales 
Incidence and outcomes
Of 442 patients who met the major haemorrhage criteria for the present study, 80⋅8 per cent were severely injured and 33⋅0 per cent had massive haemorrhage. Looking at all the 5210 trauma patients at the 22 centres during the study interval, 8⋅5 per cent had major and 2⋅8 per cent massive haemorrhage. Of all severely injured patients (ISS more than 15), 13⋅8 per cent had major haemorrhage and 5⋅0 per cent massive haemorrhage. Nationally this extrapolated to an overall incidence of 83 per million for major haemorrhage and 23 per million for massive haemorrhage. Of note, a greatly increased likelihood of major haemorrhage was identified in older patients. The likelihood of suffering injury with haemorrhage was consistent across all age groups until the age of 65 years, after which it almost doubled to 196 per million for major haemorrhage and 50 per million for massive haemorrhage (Fig. 1a) .
Overall the outcomes from trauma haemorrhage were poor ( Table 2) . One in four patients with major haemorrhage died in hospital, rising to over one in three for those with massive haemorrhage. Seventy-nine patients died within the first 24 h, representing 67⋅5 per cent of all in-hospital deaths (Fig. 1b) . More than half of the deaths on the first day occurred within the first 4 h of arrival. Mortality continued to rise after discharge, and ten further patients with major haemorrhage had died by 1 year. Overall, after 1 year around one-third of all patients had died. Extrapolating these data to the annual national estimate of 4926 patients with major haemorrhage trauma, 4128 patients would be admitted to critical care and 1635 (33⋅2 per cent) would die, 1325 (26⋅9 per cent) by 30 days.
Transfusion management
The median 24-h blood requirement was 7 units of PRBCs for the major haemorrhage group and 15 units for those with massive haemorrhage ( Table 2 ). The majority of PRBCs were transfused within the first 4 h; 36⋅0 per cent in the first hour and 54⋅8 per cent in the first 2 h (Fig. 2a) . There was a strong relationship between the number of PRBCs required in the first 24 h and mortality at 24 h (P = 0⋅002, likelihood ratio test) and 30 days (P < 0⋅001). For every additional unit of PRBCs required, the odds of death at 24 h increased by 5 per cent, and by 9 per cent per PRBC unit for 30-day mortality.
The first unit of PRBCs was received at a median of 41 min after admission. For those who received plasma, the median time to first FFP transfusion was 87 min after arrival; for patients with massive haemorrhage it was slightly faster at 68 min. The delivery of FFP fluctuated over time for individual patients and across the whole cohort, suggesting times where component therapy was not available (Fig. 2b) . In the first hour after admission, 15⋅6 per cent of patients who survived the first 24 h reached a FFP : RBC ratio of 1 : 2 or higher, 41⋅0 per cent reached the ratio within 4 h, and 55⋅4 per cent within 24 h (Fig. 2c) . No FFP was transfused at all during resuscitation in 25⋅3 per cent of patients with major haemorrhage and 8⋅2 per cent of those with massive haemorrhage. Complete transfusion component information was available for 74 of the 79 patients who died within 24 h of admission. Of these, 20 (27 per cent) died without receiving FFP and 41 (55 per cent) never reached a FFP : PRBC ratio of at least 1 : 2. Table 3 shows the results for the ratios of cumulative FFP to cumulative PRBC, for all patients who received at least 1 unit of plasma. Patients who died within 1 h were excluded from this analysis, as this group would include those who died before any plasma could be administered, had massive exsanguination and/or for whom such treatment might be considered futile. Higher FFP : PRBC ratios were associated with lower mortality rates, with no apparent difference in injury severity or physiology between the groups. Survival for patients who did not receive a balanced transfusion of FFP with PRBCs (ratio less than 1 : 2) had a 3⋅6 times higher risk of death after 3 h, and 2⋅3 times higher risk at 24 h.
There were long delays in the delivery of platelet and cryoprecipitate transfusions (Fig. 2d) . Time to first 
Discussion
Based on the present data, nearly 5000 patients have major trauma haemorrhage in England and Wales each year, and one-third of these die. Critical haemorrhage affects all age groups and is a major public health issue in many countries. Several areas of specific focus for outcomes improvement have been identified in the present study, including management in the very early phases of care to improve haemorrhage treatment. Despite a perception that many patients with major trauma are younger and typically male, the results of this study indicate that a significant proportion of patients with major haemorrhage are aged over 65 years.
The factors underlying the rise in instances of major haemorrhage in older age groups, for example more widespread use of antiplatelet or anticoagulant medications, need further evaluation.
Mortality from bleeding tends to occur early. In this study, nearly two-thirds (62⋅2 per cent, 79 of 127) of all deaths were in the first 24 h, and 28⋅3 per cent (36 of 127) within 3 h of admission. Despite advances in trauma resuscitation and surgery, management is often too slow to cope with the rapidly exsanguinating patient. Early control of bleeding is key, and the present study supports a focus on innovation in methods to control haemorrhage temporarily. Tourniquets have been reintroduced into clinical practice for extremity bleeding 20 , and there is new interest in methods of temporary control of torso haemorrhage such as balloon occlusion of the aorta 21 . Further opportunities for research and development exist for temporary haemorrhage control, including how these techniques can be deployed in the emergency department or at the incident scene.
Exsanguinating patients need optimal blood product resuscitation alongside early intervention. All participating centres had MHPs, which were not dependent on blood tests for the release of products, and advocated high ratios of plasma compared with red blood cells. Overall only 2⋅0 per cent of all patients with massive haemorrhage in the present study received what might be considered the optimal resuscitation, with a FFP : PRBC ratio of at least 1 : 2, and platelets and cryoprecipitate within the first hour of arrival 22 . As in previous studies 23, 24 , there was a survival benefit for patients who received higher doses of FFP, evident even within the first 3 h. Delivery of platelets and cryoprecipitate was delayed or even absent, an important finding especially in light of recent identification of severe fibrinogen loss in trauma-induced coagulopathy 25 .
A further finding was the variation in blood product delivery during haemorrhage management, as identified in other studies 24 . As transfusion components have to be thawed, usually in a distant laboratory, there is an almost inevitable 'boom and bust' pattern of delivery, where at certain times packs of multiple products are present and at other times none is available with teams awaiting their arrival. This often leads to an inappropriate transfusion of crystalloids or administration of vasopressors to maintain circulation, to the ultimate detriment of the patient. Some protocols manage this problem with the continuous delivery of products, but there are concerns with excessive waste using this strategy. Alternatively, clinicians need to predict ongoing transfusion requirements using clinical criteria and/or point-of-care assessments to request products earlier in the transfusion cycle. There is a clear opportunity to improve the consistency of delivery of PRBCs and coagulation components during critical haemorrhage.
Although many patients succumbed quickly from severe haemorrhage, 34 per cent of deaths among patients with massive haemorrhage occurred after the first 24 h. The actual mode of these late deaths was not collected as part of the present study, and has thus not been characterized in detail, but this finding clearly represents a further opportunity to understand and improve outcomes. Head injury was stated as a specific cause in 18⋅6 per cent of deaths in the first 24 h. Furthermore, patients who are discharged from hospital are considered to be survivors, but a further 7⋅9 per cent of deaths occurred after discharge in the present study. This may contribute to the known reduced life expectancy of patients with traumatic injuries 26 . Causes of death in these patients are almost completely unknown, and further research into the long-term mortality and functional consequences of trauma haemorrhage is required to identify opportunities for prevention of these late deaths.
There are limitations to this observational study. Data were not complete for all patients, including timings of transfusions. The inclusion criteria included activation of a MHP, to define a group of patients with severe trauma requiring significant transfusion support. Detailed information on all admissions requiring more than 4 units of PRBC transfusions was not collected, as this would include patients with surgical complications requiring transfusion. Calculations of the prevalence of severe trauma requiring more than 4 units of PRBC transfusions may have underestimated the actual prevalence. Finally, this study was undertaken at an early stage in national trauma network reorganization.
MHPs should assure early and appropriate delivery of blood components to exsanguinating patients. There is a need for a better understanding of the barriers to timely transfusion support and the implementation of haemostatic resuscitation within the framework of damage control resuscitation, which continues to be a significant challenge at many hospitals. Protocols for transfusion resuscitation may also need adapting for older patients, who more frequently have co-morbidities. The present findings provide a baseline for new initiatives and research, and a framework to understand the cost and functional burden for injured patients, which is likely to be considerable given both the prolonged stay in hospital and lost days in employment.
